Form 4: Alnylam Pharmaceuticals Director Amy Schulman Executes Option and Sells Shares Under 10b5-1 Plan

Director Amy Schulman exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 29, 2024, Amy Schulman, a director of Alnylam Pharmaceuticals, exercised stock options to acquire 30,000 shares of common stock at a price of $66.83 per share.
• Simultaneously, Schulman sold a total of 21,699 shares of common stock in multiple transactions at weighted average prices of $148.21, $148.93 and $149.76 per share.
• These transactions were executed under a Rule 10b5-1(c) trading plan adopted on February 28, 2024.
• Following these transactions, Schulman directly owns 8,436 shares of Alnylam Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors, which is important for investors to assess management's perspective on the company's value and prospects. The use of a 10b5-1 plan suggests a pre-arranged strategy to avoid accusations of trading on inside information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates